NCT03803267

Brief Summary

Colorectal cancer is the third most common cancer worldwide. These patients usually undergo open surgical resection of cancer under general anaesthesia. The aim of this study is to detect whether the Erector spinae plan block or Quadratus lumborum block will provide the most ideal analgesia for these patients. Erector spinae plan block is a novel analgesic technique that provides both visceral and somatic analgesia due to its communication with the paravertebral space. Quadratus lumborum block is a truncal nerve block usually used for intra-abdominal surgeries. Ultrasound guidance increases the accuracy and safety of both techniques. A local anaesthetic mixture of Bupivacaine 0.25% and dexamethasone will be used for both techniques.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
Completed

Started May 2019

Shorter than P25 for not_applicable colorectal-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 3, 2019

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 14, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

May 1, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2020

Completed
Last Updated

April 3, 2020

Status Verified

April 1, 2020

Enrollment Period

8 months

First QC Date

January 3, 2019

Last Update Submit

April 1, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative pain score

    The intensity of pain indicated by a segmented numeric scale in which a respondent selects a whole number (0-100 integers) that best reflects his/her pain as 0-30 for mild pain, 30-60 for moderate pain and 60-100 for sever pain

    From 1 day before the surgery to the 2 days after surgery

Secondary Outcomes (9)

  • Systolic Blood Pressure

    One hour before induction of general anesthesia, every 10 minutes till end of surgery, every 4 hours till end of the first 24 hours postoperatively, then every 8 hours till end of the next 24 hours

  • Mean Blood Pressure

    One hour before induction of general anesthesia, every 10 minutes till end of surgery, every 4 hours till end of the first 24 hours postoperatively, then every 8 hours till end of the next 24 hours

  • Heart rate

    One hour before induction of general anesthesia, every 10 minutes till end of surgery, every 4 hours till end of the first 24 hours postoperatively, then every 8 hours till end of the next 24 hours

  • Time to first rescue analgesic request

    Up to 48 postoperative hours

  • Peripheral oxygen saturation

    One hour before induction of general anesthesia, every 10 minutes till end of surgery, every 4 hours till end of the first 24 hours postoperatively, then every 8 hours till end of the next 24 hours

  • +4 more secondary outcomes

Study Arms (2)

Erector spinae plane block

ACTIVE COMPARATOR

Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique

Other: Erector spinae plane blockDrug: PropofolDrug: Fentanyl NCSDrug: Atracurium Injectable ProductOther: Endotracheal intubationDrug: Anesthesia MaintenanceDrug: Muscle Relaxation

Quadratus lumborum block

ACTIVE COMPARATOR

Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique

Other: Quadratus lumborum blockDrug: PropofolDrug: Fentanyl NCSDrug: Atracurium Injectable ProductOther: Endotracheal intubationDrug: Anesthesia MaintenanceDrug: Muscle Relaxation

Interventions

For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38\_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.

Erector spinae plane block

For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect

Quadratus lumborum block

Propofol (2 mg/kg)

Erector spinae plane blockQuadratus lumborum block

Fentanyl (1µg/Kg)

Erector spinae plane blockQuadratus lumborum block

atracurium (0.5mg/kg)

Erector spinae plane blockQuadratus lumborum block

endotracheal intubation

Erector spinae plane blockQuadratus lumborum block

Inhalational isoflurane in oxygen/air mixture

Erector spinae plane blockQuadratus lumborum block

atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia

Erector spinae plane blockQuadratus lumborum block

Eligibility Criteria

Age40 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • American Society of Anesthesiologists physical status I or II
  • Body mass index from 18.5 to 35 Kg/m2

You may not qualify if:

  • Body mass index more than 35 Kg/m2.
  • Severe or uncompensated cardiovascular disease.
  • Severe renal disease.
  • Severe hepatic disease.
  • Severe endocrinal disease.
  • Pregnancy.
  • Postpartum.
  • Lactating females
  • Allergy to one of the agents used.
  • Refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Amer A Attieh

Al Mansurah, DK, 050, Egypt

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Propofolfentanyl isothiocyanateIntubation, IntratrachealMuscle Relaxation

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsAirway ManagementTherapeuticsIntubationInvestigative TechniquesMuscle ContractionMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Amer A Attieh, MD

    Professor

    STUDY CHAIR
  • Mohammed A Ghanem, MD

    Associate Professor

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Single blind (participant) study
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 3, 2019

First Posted

January 14, 2019

Study Start

May 1, 2019

Primary Completion

January 1, 2020

Study Completion

April 1, 2020

Last Updated

April 3, 2020

Record last verified: 2020-04

Locations